You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CHK inhibitor

Showing 1 - 25 of 7,371
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Ewing Sarcoma, Ewing-Like Sarcoma Trial in New York (LY2880070, Gemcitabine)

Recruiting
  • Ewing Sarcoma
  • Ewing-Like Sarcoma
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Aug 18, 2022

Advanced Cancers Trial in Boston (LY2606368)

Active, not recruiting
Has Results
  • Advanced Cancers
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 18, 2022

NSCLC, Non-Small Cell Lung Adenocarcinoma, Non-Small Cell Squamous Lung Cancer Trial in Grand Rapids, San Antonio, Fairfax

Recruiting
  • Non-small Cell Lung Cancer
  • +10 more
  • Grand Rapids, Michigan
  • +2 more
Apr 25, 2023

Cancer Trial in Boston (LY3300054, Prexasertib)

Completed
  • Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Apr 13, 2021

Solid Tumor Trial in Boston (Prexasertib, Olaparib)

Completed
  • Solid Tumor
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Sep 1, 2021

Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Refractory Trial in Memphis (Prexasertib, Cyclophosphamide, Gemcitabine)

Active, not recruiting
  • Brain Tumor
  • +12 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Oct 20, 2022

Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL) Trial in United Kingdom (SRA737)

Completed
Has Results
  • Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
  • Sutton, London, United Kingdom
  • +14 more
Mar 9, 2022

Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma Trial in

Unknown status
  • Platinum-resistant Ovarian Cancer
  • +3 more
  • PHI-101 administration
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Jan 16, 2021

IgA Nephropathy, Immunoglobulin A Nephropathy Trial (Atrasentan, Placebo)

Not yet recruiting
  • IgA Nephropathy
  • Immunoglobulin A Nephropathy
  • (no location specified)
Apr 27, 2023

Breast Cancer Trial in Marseille (M1774, Fulvestrant injection)

Not yet recruiting
  • Breast Cancer
  • Marseille, France
    Institut Paoli Calmettes
Aug 9, 2023

Childhood Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Primary CNS Tumor Trial in United States (Laboratory Biomarker

Completed
  • Childhood Solid Neoplasm
  • +4 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Birmingham, Alabama
  • +20 more
Apr 12, 2021

Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)

Not yet recruiting
  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • (no location specified)
Aug 1, 2023

Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma Trial in Portland (Wee1

Not yet recruiting
  • Advanced Fallopian Tube Carcinoma
  • +10 more
  • Wee1 Inhibitor ZN-c3
  • Portland, Oregon
    OHSU Knight Cancer Institute
Jan 25, 2023

Acute Myeloid Leukemia, Lymphoma, Mantle-Cell Trial (PEP07)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Lymphoma, Mantle-Cell
  • (no location specified)
Dec 22, 2022

SCLC, Small Cell Cancer, Advanced Solid Tumor Trial run by the NCI (Lurbinectedin, Berzosertib)

Recruiting
  • SCLC
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Healthy Volunteers Trial in Cincinnati (CHK336, Placebo)

Recruiting
  • Healthy Volunteers
  • Cincinnati, Ohio
    Medpace Clinical Pharmacology Unit
Jan 27, 2023

Advanced Solid Tumors Trial in Spain, United Kingdom (SRA737, gemcitabine, cisplatin, SRA737, gemcitabine)

Completed
  • Advanced Solid Tumors
  • SRA737, gemcitabine, cisplatin
  • SRA737, gemcitabine
  • Barcelona, Spain
  • +19 more
Sep 23, 2020

IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome Trial in Worldwide (Atrasentan)

Recruiting
  • IgA Nephropathy
  • +5 more
  • Huntsville, Alabama
  • +37 more
Dec 1, 2022

Refractory Cancer, Refractory Tumor, Cancer Pediatric Trial in United States (9-ING-41, Irinotecan, Temozolomide)

Recruiting
  • Refractory Cancer
  • +10 more
  • Aurora, Colorado
  • +7 more
Dec 31, 2022

IgA Nephropathy, Immunoglobulin A Nephropathy Trial in Worldwide (Atrasentan, Placebo)

Recruiting
  • IgA Nephropathy
  • Immunoglobulin A Nephropathy
  • Birmingham, Alabama
  • +119 more
Aug 17, 2022

Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia Trial in United States

Active, not recruiting
  • Recurrent Acute Myeloid Leukemia
  • +3 more
  • Tampa, Florida
  • +5 more
Nov 18, 2022

Advanced Solid Tumors Trial in Houston, San Antonio, Toronto (M4076)

Recruiting
  • Advanced Solid Tumors
  • Houston, Texas
  • +2 more
Jul 13, 2022

Cancer Trial in United States (AZD2281, AZD5363, AZD1775)

Active, not recruiting
  • Cancer
  • New Haven, Connecticut
  • +3 more
Sep 14, 2021

Peripheral T Cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Peripheral T Cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing/China, China
  • +1 more
Oct 9, 2023

Cutaneous T-cell Lymphoma Trial in Beijing (Linperlisib in combined with Chidamide)

Recruiting
  • Cutaneous T-cell Lymphoma
  • Linperlisib in combined with Chidamide
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 8, 2023